Currently, TEZSPIRE is approved for severe asthma treatment in the US, EU, Japan, and nearly 60 other countries, available as a single-use pre-filled syringe and auto-injector for self ...
AstraZeneca Plc (NASDAQ:AZN) and Amgen Inc (NASDAQ:AMGN) released topline data from the Phase 3 WAYPOINT trial of Tezspire ...
Tezspire is currently approved for severe asthma in the US, EU, Japan, and nearly 60 countries. It is approved as a single-use pre-filled syringe and auto-injector for self-administration in the ...
2-5 It is approved as a single-use pre-filled syringe and auto-injector for self-administration in the US and EU.2,3 TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric ...
Tezspire is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. It is approved as a single-use pre-filled syringe and auto-injector ...
Already approved for severe asthma in multiple countries, Tezspire is available in pre-filled syringes and auto-injectors for ...
TEZSPIRE is currently approved for the treatment of severe asthma in the US, EU, Japan, and nearly 60 countries across the globe. 2-5 It is approved as a single-use pre-filled syringe and auto ...
The differences between PFSs and MDVs (per 1000 doses) is 324.21. MDV: Multidose vial; NA: Not available; PFS: Prefilled syringe. Prefilled syringes (PFSs) have gained market share in the USA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback